What does Wegovy weight loss success actually look like?

What do the trial results actually tell us about Wegovy success?

The STEP 1 trial enrolled 1,961 adults with obesity or overweight and at least one weight-related condition, none of whom had type 2 diabetes. At 68 weeks, those taking semaglutide 2.4 mg lost an average of around 15% of their body weight compared with roughly 2.4% in the placebo group. Averages, though, can obscure the range. Around a third of participants exceeded 20% weight loss; a smaller proportion lost less than 5%. That spread is clinically important, because NICE's recommendation for semaglutide (published as NICE technology appraisal TA875) includes a review point at six months: if someone has not lost at least 5% of their starting weight on the maintenance dose, continuing treatment should be reconsidered.

The 2026 approval of the 7.2 mg dose adds a new ceiling. Trials at that strength reported an average of around 20.7% weight loss over 72 weeks, narrowing the gap with tirzepatide's headline figures. Whether 7.2 mg becomes your maintenance dose is a decision made with your prescriber, not one you choose in advance. You can read more about how the evidence compares across doses on our dedicated Wegovy effectiveness page.

Why does success vary so much from person to person?

A question our prescribers hear regularly is: why did my friend lose so much more than I did? Semaglutide works by activating GLP-1 receptors that regulate appetite and slow gastric emptying, but the degree to which any individual's appetite responds is not uniform. Genetic factors, gut-hormone sensitivity, baseline metabolic rate, and how consistently a person manages the lifestyle component all influence the result.

Dose titration matters too. Treatment starts at 0.25 mg to let the body adjust gradually; the therapeutic effect builds as the dose rises through the schedule toward 2.4 mg. People who experience side effects severe enough to delay titration may spend longer at lower doses, which affects the weight-loss curve. The lifestyle piece is not decorative. The STEP 1 trial ran alongside structured diet and activity support, and removing that context tends to reduce outcomes. Our practical guide on getting the most from Wegovy covers how to approach this alongside treatment.

It is also worth knowing that weight loss typically accelerates in the first three to six months, then slows. A plateau in months seven or eight is not failure; it is the expected shape of the response curve.

What happens when Wegovy is stopped, and does that affect how success is defined?

One of the most honest things to say about Wegovy is that, for many people, weight regain follows if treatment ends. This was documented in follow-up analyses of the STEP trials: participants who stopped semaglutide after the active phase regained a substantial portion of the weight lost within a year. That does not mean Wegovy is only useful indefinitely (for some people, a defined course produces lasting changes in eating behaviour) but it does mean that success is better framed as ongoing health management than as a one-time intervention. If you want a sense of what that journey can look like in practice, reading a real Wegovy success story can help put the clinical picture into a more personal context.

NICE's appraisal of semaglutide specifies a maximum treatment duration of two years within specialist NHS services. Private treatment through a regulated pharmacy like our clinical team at nume operates under the same clinical standards, with a prescriber reviewing your progress before each repeat supply. Planning for what comes after (whether that is continuing treatment, transitioning to lifestyle maintenance, or a different approach) is part of the clinical conversation from the start.

What does the treatment experience look like week to week?

Wegovy arrives as a pre-filled injection pen. When ordered through a GPhC-registered online pharmacy, it comes in plain, unbranded packaging via a tracked DPD delivery, you get a notification when it is on its way, so there is no need to wait in all day. The pen itself is self-administered once a week, typically at the same time on the same day, rotating injection sites between the abdomen, thigh and upper arm.

The most commonly reported side effects are gastrointestinal: nausea, constipation, and occasionally vomiting, particularly in the early weeks or after a dose increase. For most people these settle with time, though they can be uncomfortable. Staying well hydrated and eating smaller portions helps many people manage. If you are thinking about starting, our guide to success with Wegovy covers what realistic progress looks like from the first injection through to the maintenance phase, and our Wegovy success rate page goes deeper on how results are measured across the clinical programme. Reading our full Wegovy guide also gives a thorough picture of what to expect.

Success is not a single number. It is the weight lost, how long it is maintained, what changes in energy and health markers alongside it, and how manageable the treatment feels over time. If you want to explore whether Wegovy might be appropriate for you, speaking to our prescribers is a straightforward first step.